LEAP4WA PUBLICATIONS
Swati Gupta; Donald Grant, Robert Garry, Abdulwasiu Bolagi Tiamiyu, Sandhya Vasan, Stephen Kennedy, Bernice Dahn, James Duworko, Rebecca Grais, Marija Zaric, Patricia Fast; Gaudensia Mutua, Devin Hunt, Kathleen Walker, Shaun Palmer, Bridgette Connell, Jennifer Lehrman; LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 11th EDCTP Forum. November 2023.
An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. LEAP4WA will conduct a Phase IIb efficacy trial, evaluating the efficacy of VSV∆G-LASV-GPC for the prevention of laboratory confirmed, symptomatic Lassa fever in a West African LASV-NP seronegative population.
LEAP4WA will also develop state-of-the-art clinical research capacity in West Africa that can be utilized for other Emerging Infectious Diseases in the future.
PUBLICATIONS
OTHER RELEVANT PUBLICATIONS
Moore KA, Ostrowsky JT, Mehr AJ, Johnson RA, Ulrich AK, Moua NM, et al. (2024). Lassa fever research priorities: towards effective medical countermeasures by the end of the decade. Lancet Infect Dis. doi.org/10.1016/S1473-3099(24)00229-9.
Lawal QO. (2024). Untold Lassa fever story: a physician’s lived experience. Lancet Infection 24, e277(2024). doi.org/10.1016/ S1473-3099(24)00148-8.
Vora NM, Hannah L, Walzer C, Vale MM, Lieberman S, Emerson A, et al. (2023). Interventions to Reduce Risk for Pathogen Spillover and Early Disease Spread to Prevent Outbreaks, Epidemics, and Pandemics. Emerg Infect Dis. doi.org/10.3201/eid2903.221079
Penfold S, Adegnika AA, Asogun D, Ayodeji O, Azuogo BN, Fischer II WA et al. (2023). A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme) – Study protocol. PLoS ONE. doi.org/10.1371/journal.pone.0283643
Klitting R, Kafetzopoulou LE, Thiery W, Dudas G, Gryseels S, Kotamarthi A, et al. (2022). Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. Nat Commun 13, 5596. doi.org/10.1038/s41467-022-33112-3
Garry R. (2022). Lassa fever — the road ahead. Nat Rev Microbiol 21, 87–96. doi.org/10.1038/s41579-022-00789-8
Hastie KM, Zandonatti MA, Kleinfelter LM, Heinrich ML, Rowland M, Chandran K, et al. (2017). Structural basis for antibody-mediated neutralization of Lassa Virus. Science 356,923-928(2017). doi.org/10.1126/science.aam7260
Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H. (2015). A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. PLoS Negl Trop Dis.17;9(4):e0003736. doi: 10.1371/journal.pntd.0003736. PMID: 25884628; PMCID: PMC4401668.
Swati Gupta; Patricia Fast; Jennifer Lehrman; Matt Price; LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 10th EDCTP Forum. October 2021.
An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. The vaccine candidate demonstrated 100% efficacy against LASV in a nonhuman primate challenge study. Furthermore, it uses the same technology as Merck’s ERVEBO® vaccine, which has been shown to be safe and efficacious in preventing Ebola virus disease and is licensed in multiple countries.